Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...
The guidelines include recommendations for first-, second-, and third-line therapy. The American Society of Clinical Oncology (ASCO) has updated its guidelines on the use of systemic therapy for ...
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer Liver transplantation (LT) has been accepted as a cornerstone of care in hepatocellular carcinoma ...
Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...
10d
A machine learning model may enable liver cancer risk prediction with routine clinical information
A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results ...
Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery. Administering ...
Using routine clinical data, the model gauges liver cancer risk better than existing tools, offering a potential way to identify high-risk patients missed by current screening criteria.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results